| Literature DB >> 31073315 |
Mst Marium Begum1,2, Azharul Islam3, Rayhana Begum2, Md Sahab Uddin4, Md Sohanur Rahman1, Sumiya Alam2, Wahida Akter2, Munny Das6, Md Sohanur Rahman1, A H M Rahmatullah Imon7.
Abstract
The stem bark of Oroxylum indicum (O. indicum) was aimed at testing for anti-inflammatory, antiulcerative, antihyperglycemic, and antidyslipidemic activities. Liver enzyme concentration (SGPT, SGOT) had also been assessed. After being extracted in organic solvent, 3 distinct doses, 100, 200, and 400 mg/kg b.w. (p.o.), were used. For edema formation 0.1 ml carrageenan at a dose of 1% w/v was injected into paw of left hind. It showed a fall of edemas 37.50%, 48.34%, and 55.83% while used doses were 100, 200, and 400 mg/kg b.w. (p.o.) individually. The EtOH extract of O. indicum (50%) and its fractions PET, CLF, EtOAc, and nBUT were studied against ethanol-induced gastric mucosal damage. Only PET and n-BuOH exhibited the highest percentage of protection and were 96% and 99%, respectively, persuaded by ethanol. In OGTT glibenclamide revealed reduction of glucose level to 7.55 ± 0.22 mmol/L from 10.57 ± 0.32 mmol/L after 30 minutes. Antihyperglycemic activities were assessed for 8- and 12-week duration in diabetic rats. Glibenclamide reduced glucose level from 33.50±0.31 to 7.90±0.19 mmol/L in 12 weeks. In 12 and 8 weeks, combination therapy lowered blood glucose level to a normal extent by 79% and 61% individually. In antidyslipidemic activities after 12-week treatment, it revealed simvastatin; MEOI (400 mg/kg b.w.) and combination of both reduced TC level by 44%, 28%, and 48% consequently followed by TG and LDL. In 8-week treatment, HDL levels were increased by 34%, 13%, and 36%, and in 12 weeks increased by 36%, 8%, and 38% consequently. Liver enzyme concentration after 12 weeks of treatment with glibenclamide, 400 mg/kg b.w. (p.o.) of MEOI and combination of both, exhibited the fact that concentration of SGPT showed downturn by 43.23%, 8.01%, and 54.86% and SGOT by 42.40%, 5.31%, and 44.85%. This study remarked that O. indicum has anti-inflammatory, antiulcer, antidiabetic, and antidyslipidemic potentials but has no ameliorative effect on liver enzyme.Entities:
Year: 2019 PMID: 31073315 PMCID: PMC6470466 DOI: 10.1155/2019/1562038
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Anti-inflammatory effect of MEOI on carrageenan-induced changes in paw thickness in experimental rats.
| Groups | NC | CC | IP-20 | MEOI-100 | MEOI-200 | MEOI-400 |
|---|---|---|---|---|---|---|
| Dose | – | – | Ibuprofen 20 | Extract 100 | Extract 200 | Extract 400 |
| Initial paw thickness | 0.54±0.04 | 0.43±0.07 | 0.51±0.06 | 0.52±0.04 | 0.47±0.07 | 0.50±0.04 |
| Paw thickness after 1 hr | 0.54±0.03 | 0.69±0.05 | 0.60±0.04 | 0.68±0.07 | 0.64±0.05 | 0.59±0.06 |
| Paw thickness after 2 hrs | 0.54±0.04 | 0.85±0.05 | 0.64±0.05 | 0.75±0.04 | 0.68±0.05 | 0.62±0.06 |
| Paw thickness after 3 hrs | 0.54±0.05 | 0.98±0.06 | 0.68±0.07 | 0.80±0.05 | 0.72±0.06 | 0.65±0.05 |
| Paw thickness after 4 hrs | 0.54±0.06 | 1.15±0.08 | 0.70±0.06 | 0.83±0.07 | 0.75±0.07 | 0.67±0.09 |
| Paw thickness after 5 hrs | 0.54±0.05 | 1.18±0.09 | 0.63±0.07 | 0.79±0.09 | 0.71±0.06 | 0.61±0.06 |
| Paw thickness after 6 hrs | 0.54±0.06 | 1.20±0.07 | 0.56±0.06 | 0.75±0.08 | 0.62±0.07 | 0.53±0.07 |
Observed values were represented by mean ± SEM (n=6). p < 0.05 and p < 0.01 when compared with control group.
NN = normal control, CC = carrageenan control, IP = ibuprofen 20 mg/kg b.w., MEOI-100 = 100 mg/kg b.w./day methanolic extract of O. indicum, MEOI-200=200 mg/kg b.w./day methanolic extract of O. indicum, and MEOI-400 = 400 mg/kg b.w./day methanolic extract of O. indicum.
Figure 1Histological analysis of paw tissue in the carrageenan-induced paw edema model. Each picture is representative of each group as follows: (a) normal control, (b) carrageenan control, (c) ibuprofen 20 mg/kg b.w., (d) 100 mg/kg b.w./day methanolic extract of O. indicum, (e) 200 mg/kg b.w./day methanolic extract of O. indicum, and (f) 400 mg/kg b.w./day methanolic extract of O. indicum. IC, inflammatory cells; arrow indicates infiltration of inflammatory cells. Each group was assessed at 400X magnification, and the scale bar is 40μm.
Antiulcer effect of EtOHand its fractionsin experimental rats.
| Groups | Ulcer indexed | Ulcer inhibition (%) |
|---|---|---|
| Control | 7.04±0.112 | – |
| EtOH (50%) | 0.65±0.035 | 89.29 |
| EtOAc | 0.87±0.044 | 86.12 |
| CLF | 0.58± 0.05 | 91.50 |
| PET | 0.27±0.011 | 95.80 |
| nBUT | 0.07±0.007 | 98.60 |
| Omeprazole | 0.75±0.042 | 88.70 |
Observed values were represented by mean ± SEM (n=6).
Effect of glibenclamide on blood glucose level.
| Time (hour) | Glucose control | Glucose+Glibenclamide |
|---|---|---|
| 0 | 6.23±0.17 | 6.78±0.27 |
| 0.5 | 10.57±0.32 | 7.55±0.22 |
| 1 | 7.66±0.17 | 6.1±0.19 |
| 2 | 6.12±0.08 | 5.34±0.03 |
Observed values were represented by mean ± SEM (n=6).
Effect of glibenclamide, MEOI, and combination therapy on blood glucose level in 8-week treatment protocol.
| Time duration |
| ||||
|---|---|---|---|---|---|
| Control | Diabetic control | Alloxan+Glibenclamide | Alloxan+400 mg/kgb.w. | Alloxan+Combination | |
| Before 8 weeks | 6.58 ± 0.09 | 16.28 ± 0.12 | 16.36 ± 0.14 | 16.41 ± 0.15 | 16.2 ± 0.13 |
| After 8 weeks | 6.53 ± 0.23 | 16.75 ± 0.23 | 7.31 ± 0.21 | 12.2 ± 0.17 | 6.4 ± 0.09 |
Observed values were represented by mean ± SEM (n=6). p < 0.05 when compared with control group.
Effect of glibenclamide, MEOI, and combination therapy on blood glucose level in 12-week treatment protocol.
| Time duration |
| ||||
|---|---|---|---|---|---|
| Control | Diabetic control | Alloxan+Glibenclamide | Alloxan+400 mg/kg b.w. | Alloxan+Combination | |
| Before 12 weeks | 6.43 ± 0.29 | 34.58 ± 0.12 | 33.50 ± 0.31 | 32.96 ± 0.34 | 34.50 ± 0.21 |
| After 12 weeks | 6.58 ± 0.23 | 34.73 ± 0.45 | 7.90 ± 0.19 | 20.34 ± 0.13 | 7.30 ± 0.10 |
Observed values were represented by mean ± SEM (n=6). p < 0.05 when compared with control group.
Effect of simvastatin, MEOI, and combination therapy on total cholesterol level in 8- and 12-week treatment protocol.
| Time duration |
| ||||
|---|---|---|---|---|---|
| Control | Diabetic control | Alloxan+Simvastatin | Alloxan+400 mg/kg b.w. | Alloxan+Combination | |
| TC in 8 weeks | 165.25 ± 2.2 | 263 ± 3.45 | 158 ± 2.39 | 206 ± 2.1 | 148 ± 2.0 |
| TC in 12 weeks | 165 ± 1.90 | 278 ± 3.10 | 156 ± 1.97 | 201 ± 1.1 | 144 ± 0.90 |
Observed values were represented by mean ± SEM (n=6). p < 0.05 when compared with control group.
Effect of simvastatin, MEOI, and combination therapy on triglycerides level in 8- and 12-week treatment protocol.
| Time duration |
| ||||
|---|---|---|---|---|---|
| Control | Diabetic control | Alloxan+Simvastatin | Alloxan+400 mg/kg b.w. | Alloxan+Combination | |
| TG in 8 weeks | 120.5 ± 8.08 | 193.5 ± 2.39 | 131.4±2.01 | 164.5 ± 1.31 | 125 ± 1.1 |
| TG in 12 weeks | 125 ± 0.23 | 192.2 ± 0.23 | 130± 0.21 | 160 ± 0.13 | 123 ± 0.12 |
Observed values were represented by mean ± SEM (n=6). p < 0.05 when compared with control group.
Effect of simvastatin, MEOI, and combination therapy on low-density lipoprotein level in 8- and 12-week treatment protocol.
| Time duration |
| ||||
|---|---|---|---|---|---|
| Control | Diabetic control | Alloxan+Simvastatin | Alloxan+400 mg/kg b.w | Alloxan+Combination | |
| LDL in 8 weeks | 124 ± 2.4 | 185.75 ± 2.7 | 135 ± 1.4 | 178 ± 1.4 | 128 ± 1.2 |
| LDL in 12 weeks | 125.75±2.1 | 182.25 ± 2.3 | 130.5±1.2 | 173 ± 1.1 | 123 ± 1.1 |
Observed values were represented by mean ± SEM (n=6). p < 0.05 when compared with control group.
Effect of simvastatin, MEOI, and combination therapy on high-density lipoprotein level in 8- and 12-week treatment protocol.
| Time duration |
| ||||
|---|---|---|---|---|---|
| Control | Diabetic control | Alloxan+Simvastatin | Alloxan+400 mg/kg b.w. | Alloxan+Combination | |
| HDL in 8 weeks | 55.25±1.25 | 34.75 ± 0.85 | 52.5 ± 0.83 | 40.25 ±0.64 | 55 ± 0.5 |
| HDL in 12 weeks | 54.41±1.10 | 36.50 ± 1.19 | 42 ± 0.47 | 55.59 ± 0.85 | 58 ± 0.45 |
Observed values were represented by mean ± SEM (n=6). p < 0.05 when compared with control group.
Effect on liver enzyme concentration fluctuated after 8 weeks of treatment.
| Liver enzyme concentration (U/L) |
| ||||
|---|---|---|---|---|---|
| Normal | Alloxan | Alloxan+Glibenclamide | Alloxan+MEOI 400mg/kg b.w. | Alloxan+Combination | |
| SGPT | 25.65 ± 0.63 | 77.11 ± 1.36 | 44.74 ± 0.95 | 71.5 ± 0.87 | 35.00 ± 0.98 |
| SGOT | 34.65 ± 0.51 | 73.75 ± 0.35 | 43.25 ± 0.58 | 70.25 ± 0.55 | 42.55 ± 0.76 |
Observed values were represented by mean ± SEM (n=6).
Effect on liver enzyme concentration fluctuated after 12 weeks of treatment.
|
| |||||
|---|---|---|---|---|---|
| Liver enzyems concentration (U/L) | Normal | Alloxan | Alloxan+Glibenclamide | Alloxan+MEOI | Alloxan+Combination |
| SGPT | 24.75±0.63 | 73.11±1.26 | 41.50±0.85 | 67.25±0.64 | 33.00±1.47 |
| SGOT | 32.34±0.41 | 75.25±0.85 | 43.34±0.48 | 71.25±0.85 | 41.50±0.85 |
Observed values were represented by mean ± SEM (n=6).